Latest Urology News
Nocturia improved 43% in patients receiving oral desmopressin alone and 64.3% in those receiving desmopressin and an alpha-blocker.
Study authors developed a Markov model with health states based on daily urinary incontinence episodes (UIEs) to compare the cost-effectiveness of onabotulinumtoxinA, implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications, and mirabegron versus BSC for the management of refractory OAB.
UROPP reduces opioids prescribed after gynecologic, abdominal surgery without negative effects.
Hypogonadism and serum testosterone evaluation nearly doubled the odds a man would undergo varicocelectomy.
IBD is associated with a nearly 5-fold increased risk of prostate cancer, study finds.
Patients with muscle-invasive bladder cancer had a 22% decreased risk of disease progression if they received neoadjuvant rather than adjuvant chemotherapy, a study found.
More than half of UK specialists surveyed said measuring testosterone levels in patients with nonmetastatic prostate cancer was not their routine practice.
Risk for patients in rivaroxaban group reduced during the on-treatment period
In a study, the rate of deep vein thrombosis in treated hypogonadal men was just 0.8% over 2 years of follow-up.
Method evaluating cells collected from urine shows 94% diagnostic accuracy.
Lymph node dissection did not influence overall survival even among patients with clinically positive nodal disease.
Prior to starting Xyosted, the patient's baseline cardiovascular risk should be considered and blood pressure should be adequately controlled.
Men with Gleason score 9 to 10 prostate cancer derive no significant survival benefit from androgen deprivation therapy.
Well demarcated hypoechoic areas in suspicious regions on MRI identify men more likely to have Gleason 7 or higher prostate cancer found on biopsy.
Overweight and obesity, diabetes, and postoperative complications increase the likelihood of being readmitted within 30 days of hospital discharge among radical cystectomy patients.
In a study, taking lipid-lowering drugs for 10 or more years was associated with a 32% lower risk prostate cancer.
Drug targets solid tumors with NTRK gene fusion without a known acquired resistance mutation
Patients whose radical prostatectomy was delayed more than 6 months had a nearly 2-fold increased risk of biochemical recurrence, a study found.
Targeted patient-centered intervention reduces nonadministration of pharmacologic prophylaxis.
Men with very high-risk (VHR) PCa are more likely to have adverse pathologic features and outcomes after radical prostatectomy than those with high-risk but not VHR PCa.
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)